volibris
glaxosmithkline (ireland) limited - ambrisentaania - hypertensio, keuhkokuume - verenpainelääkkeet, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.
xarelto
bayer ag - rivaroksabaani - arthroplasty, replacement; venous thromboembolism - antitromboottiset aineet - xarelto-valmistetta, samanaikaisesti asetyylisalisyylihapon (asa) yksin tai yhdessä asa plus klopidogreeli tai tiklopidiini, on tarkoitettu aterotromboottisten tapahtumien estämiseen aikuispotilaille, kun akuutti koronaarioireyhtymä (acs) kanssa sydänperäisten biomerkkiaineiden kohoamista. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. laskimotromboembolian (vte) ehkäisy aikuisilla potilailla, jotka saavat elektiivisen lonkan tai polven korvaavan leikkauksen. hoito syvä laskimotukos (dvt) ja keuhkoembolian (pe), ja toistuvien dvt ja pe aikuisilla. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
sukolin 50 mg/ml injektio-/infuusioneste, liuos
orion corporation - suxamethonium chloride dihydrate - injektio-/infuusioneste, liuos - 50 mg/ml - suksametoni
glycostigmin injektioneste, liuos
takeda oy - glycopyrronium bromide, neostigmine metilsulfate - injektioneste, liuos - neostigmiini
xalatan 50 mikrog/ml silmätipat, liuos
upjohn eesv - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti
isotretinoin orifarm 10 mg kapseli, pehmeä
orifarm generics a/s orifarm generics a/s - isotretinoinum - kapseli, pehmeä - 10 mg - isotretinoiini
latanoprost ratiopharm 50 mikrog/ml silmätipat, liuos
ratiopharm gmbh - latanoprostum - silmätipat, liuos - 50 mikrog/ml - latanoprosti
latanoprost sandoz 50 mikrog/ml silmätipat, liuos
sandoz a/s - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti
oftastad 50 mikrog/ml silmätipat, liuos
stada arzneimittel ag - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti
latanoprost pfizer 50 mikrog/ml silmätipat, liuos
upjohn eesv - latanoprost - silmätipat, liuos - 50 mikrog/ml - latanoprosti